Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study

• DOI: 10.1186/s12941-015-0107-z
• Publication Date: 2015-11-04T03:34:34Z
• Authors: Seniha Senbayrak; Nuri Ozkutuk; Hakan Erdem; Isik Somuncu Joha...; Rok Civljak; Ayse Seza Inal; Uner Kayabas; Ebru Kursun; Nazif Elaldi; Branislava Savic; Soline Simeon; Emel Yilmaz; Olga Dulovic; Derya Ozturk-Engin; Nurgul Ceran; Botond Lakatos; Oguz Resat Sipahi; Mustafa Sunbul; Mucahit Yemisen; Selma Alabay; Bojana Beovic; Aysegul Ulu-Kilic; Yasemin Cag; Melanie Catroux; Asuman Inan; Gorana Dragovac; Ozcan Deveci; Recep Tekin; Hanefi Cem Gul; Gonul Sengoz; Katell Andre; Arjan Harxhi; Yves Hansmann; Serkan Oncu; Sukran Kose; Oral Oncul; Emine Parlak; Alper Sener; Gulden Yilmaz; Umit Savasci; Haluk Vahaboglu
• Keywords: Tuberculous Meningitis; Medical microbiology; Pyrazinamide

Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed evaluate drug resistance profiles of TBM isolates in adult patients nine European countries involving 32 centers provide insight into the empiric treatment TBM. was cultured from cerebrospinal fluid (CSF) 142 and tested for susceptibility first-line drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) ethambutol (EMB). Twenty (14.1 %) were at least one drug, five (3.5 INH RIF, [multidrug (MDR)]. The rate 12, 4.9, 4.2 3.5 % INH, SM, EMB respectively. monoresistance 6.3, 1.4 0.7 SM There no RIF. mortality 23.8 fully susceptible cases while it 33.3 those exhibiting 40 with MDR-TBM. In compared without any relative risk death INH-monoresistance MDR-TBM 1.60 (95 CI, 0.38–6.82) 2.14 0:34–13:42), INH-resistance MDR rates seemed not be worrisome our study. However, considering their adverse effects on treatment, rapid detection RIF would most beneficial designing anti-TB therapy. Still, should started immediately waiting testing.